Patent expiration can change the very course of a market. In the case of the asthma therapeutics market however, the impact will be evident, but not devastating. Leading brands will certainly suffer to a marked degree with the expiration of key drugs such as Singulair, Advair, and Symbicort. Despite this, the asthma therapeutics market in the eight leading developed nations will likely brave the headwinds and register a CAGR of 2.4% between 2013 and 2020.
According to a recent research report, the market for asthma therapeutics was valued at US$18.4 billion as of 2013, and will expand to an estimated US$21.7 billion by the end of 2020. Moving forward, stakeholders and companies can expect a marginal rate of growth in the asthma therapeutics market, which can be successfully sustained via the launch of innovative and affordable therapies.
Blow From Asthma Therapeutics Patent Expiration to be Softened by These Two Important Drivers
The restraining forces in the asthma therapeutics market will be balanced by two important drivers: The rising prevalence of asthma and new players foraying into the market.
According to market research analysts, the number of people suffering from asthma in the world is pegged at to rocket to an alarming 400 million by 2025. The sheer numbers of asthma patients, many of whom are located in increasingly affluent emerging economies, will create an organic demand for asthma therapeutics. Encouraged by this hitherto untapped consumer base, several new entrants are expected to make their presence felt in the asthma therapeutics market.
These two factors will be important in the long run because they will prevent the market from reaching a point of stagnation.
Browse the Full Global Asthma Therapeutics Market Report : http://www.mrrse.com/asthma-therapeutics-market

Monoclonal Antibodies and Biologics to Attract Immense Interest from Pharmaceutical Industry
The current pool of asthma therapeutics is seen to be satisfactory in terms of helping patients manage symptoms. However, there are still some patients that are unable to effectively control their condition using currently-available products. As a result, the asthma therapeutics market carries a small but significant unmet need, which is further compounded by the pervasiveness of asthma. All of these factors have stirred the interest of pharmaceutical companies in the asthma therapeutics industry.
Another factor that will greatly benefit the market is the presence of an asthma therapeutics pipeline teeming with novel molecules. Many of these promising molecules are currently reported to be in the late-stage of development. Industry interest is particularly strong in monoclonal antibodies such as lebrikizumab, mepolizumab, dupilumab and reslizumab – all of which directly target Interleukins receptors or ILs themselves. These therapies could provide pioneering treatment for patients suffering from severe eosinophilic asthma not adequately controlled.
Personalized Therapy Carries Definite Revenue Generation Opportunity
Personalized therapy—though it caters to a small sub-set of patients—will be a trend to watch out for in the coming years. Given their high price tags, revenues from personalized therapy drugs will be higher, and will possibly steer the market toward faster growth.
All of these factors will fuse together over the next few years to help alleviate the impact of patent expiration and the resultant generic erosion.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Symptoms
2.6 Diagnosis
2.7 Assessment of Disease Severity
2.8 Treatment
2.9 Treatment Algorithm
2.10 Treatment Segments
2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma
2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy
2.10.3 ICS/LABA Combination Therapy
2.10.4 Add-on Therapies

3 Marketed Products
3.1 Overview
3.2 ICS for the Maintenance Treatment of Asthma
3.2.1 Arnuity (fluticasone furoate) – GSK
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) – GSK
3.3.2 Symbicort (budesonide and formoterol fumarate) – AstraZeneca, Co-Promotion with Astellas Pharma
3.3.3 Dulera (mometasone furoate and formoterol fumarate) – Merck
3.3.4 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) – GlaxoSmithKline/Theravance
3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
3.4.1 Xolair (omalizumab) – Novartis and Genentech
3.4.2 Singulair (montelukast) – Merck
3.4.3 Spiriva (tiotropium bromide) – Boehringer Ingelheim
3.5 Heat Maps for Marketed Products

Send An Enquiry : http://www.mrrse.com/enquiry/106

4 Asthma Pipeline
4.1 Overview
4.2 Pipeline Analysis by Stage of Development, Molecule Type and Program Type
4.3 Pipeline Analysis by Molecular Target
4.4 Asthma Clinical Trial Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Comparative Clinical Trial Metrics Analysis
4.5 Promising Pipeline Molecules
4.5.1 Mepolizumab – GSK
4.5.2 Reslizumab – Teva Pharmaceutical
4.5.3 Lebrikizumab – Roche/Genentech
4.5.4 Dupilumab – Regeneron Pharmaceuticals in Collaboration with Sanofi
4.5.5 Masitinib – AB Science
4.6 Heat Map and Competitor Matrix for Pipeline Products

5 Market Forecast to 2020
5.1 Geographical Markets
5.2 Global Market
5.3 North America
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Top Five Countries of Europe
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Asthma Market
5.6.1 Drivers
5.6.2 Barriers

6 Strategic Consolidations
6.1 Co-development Deals
6.1.1 Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide
6.1.2 NeoStem Enters into Agreement with University of California to Develop Human Regulatory T Cells
6.1.3 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies
6.2 Licensing Deals
6.2.1 Amgen Enters into Licensing Agreement with Kyowa Hakko Kirin – Terminated
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma
6.2.3 MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca – Terminated
6.2.4 Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals – Terminated
6.2.5 Aslan Pharma Enters into Licensing Agreement with CSL for CSL-334

UpComing Report :
• Profenofos Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 – 2020
http://www.mrrse.com/profenofos-market
Profenofos is an organophosphorus insecticide which is used to kill pests that damage crop and thus, affects the overall agricultural productivity. Profenofos chemical name is 0-4-bromo-2- chlorophenyl Oethyl S-propyl phosphorothioate. The molecular weight of profenofos is approximately 373. Profenofos is used as an ovicide and larvicide in order to kill insects and larvae of various insects. Profenofos intoxication has resulted mainly due to the accumulation of acetylcholine at the nerve endings. Profenofos is an amber coloured liquid. Profenofos generally has a garlic-like odour. Profenofos has a boiling point of 110oC. Profenofos is usually stable at neutral and slightly acidic conditions however; profenofos turns unstable under alkaline conditions. Profenofos being highly soluble in organic solvents helps in easy application of insecticides on plants. Profenofos is highly flammable in nature owing to the chemical properties of the solvents in which it is dissolved.
• Polyethylene Terephthalate (PET) Resin Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 – 2020
http://www.mrrse.com/polyethylene-terephthalate-resin-market
Polyethylene terephthalate (PET) is a thermoplastic polymer that belongs to the family of polyester. Polyethylene terephthalate resin was introduced for commercial use as textile fiber and film in 1953. Polyethylene terephthalate (PET) in its natural state is semi-crystalline colorless resin. Polyethylene terephthalate varies from semi rigid to rigid mainly on the basis of the method used for processing it. Polyethylene terephthalate is light weight in nature and has good gas barrier and alcohol barrier properties. PET becomes white when it is exposed to chloroform and other chemicals such as toluene. Polyethylene terephthalate is generally manufactured from terephthalic acid or dimethyl terephthalate and ethylene glycol. PET offers excellent wear resistance, high flexural modulus, superior dimensional stability and low coefficient of friction.

About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.


Contact Us:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: [email protected]
Website: http://www.mrrse.com/
Blog: http://mrrse.blogspot.com/